Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

Charles River Laboratories Intl. IncTrade
GraniteShares 2x Long NVDA Daily ETFTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.76 (market cap $11.14B), while GraniteShares 2x Long NVDA Daily ETF trades at $32.36. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.

CRLNVDL
Market Cap
$11.14B
Sector
HealthLeveraged / Inverse
52-Week High
$233.60$43.02
52-Week Low
$145.57$21.76
Enterprise Value
$14.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

GraniteShares 2x Long NVDA Daily ETF

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.7, down 7.05% in the last 24 hours, reflecting high volatility tied to its leveraged exposure to NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. Recent stock splits on June 25 and 26, 2026, adjusted the share structure, but key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. The ETF's performance is directly driven by daily NVIDIA price movements, amplified by its 2x leverage.

The outlook for NVDL hinges on NVIDIA's AI-driven growth, offering potential for high returns but with significant risk due to leverage compounding losses during downturns. Investors face volatility risks, as seen in a 12% single-day drop on June 5, 2026, and must monitor NVIDIA's earnings and broader semiconductor trends. Caution is advised given the lack of traditional fundamentals and the ETF's reset mechanism, which can erode value over time in volatile markets.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

Read more on NVDL